Ferrari’s Lewis Hamilton and Charles Leclerc shared differing opinions when it came to their success in Qualifying for the Dutch Grand Prix.
Chris Medland picks out five key things to keep an eye on when the lights go out on race day at Zandvoort.
George Russell was keen to focus on the positives after he missed out on pole position for the Dutch Grand Prix to McLaren’s Lando Norris.
Seventh place was not what Max Verstappen had hoped for in Qualifying at the Dutch Grand Prix, the Red Bull driver lining up one spot ahead of stand-in team mate Liam Lawson.
Payton Westcott dominated Saturday's Reverse Grid Race to seal her maiden F1 ACADEMY victory.
Off the back of his winning weekend last time out in Hungary, McLaren's Lando Norris made it back-to-back pole positions in Qualifying for the Dutch Grand Prix.
Reuters reports "a major success in a new field of cancer treatment this week, as Moderna and Merck announced a personalized mRNA cancer vaccine "reduced the risk of recurrence and spread of melanoma in a late-stage trial". The vaccine was tested with Merck's widely used immunotherapy drug Keytruda:
Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview. This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system to fight tumors by targeting specific mutations in those cells, and the first such study to show that adding a treatment to Keytruda worked better than that therapy alone... Interim results of the ongoing study, released on Wednesday, found the treatment, Intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of preventing tumors from spreading to other parts of the body, compared with Keytruda alone. When the vaccine is injected into a patient, the patient's cells produce copies of mutations for the immune system to recognize and destroy... Merck said the companies are already in talks with regulators about the treatment.
"Merck, Moderna and other companies are testing similar approaches against lung, breast and pancreatic cancers," the article points out. It adds that Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, "said the Moderna results could signal a new era for treating solid-tumor cancers."
More from CNN:
The trial result is "a monumental leap forward," validating mRNA technology as a cancer treatment, said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology...
Roche and BioNTech, whose mRNA technology was used in the Pfizer COVID vaccines, are testing a similar treatment called autogene cevumeran in mid-stage studies in colon and pancreatic cancer patients who have undergone surgery. Results of the colon cancer trial are expected in 2027, with pancreatic trial results to follow in 2031. "We should be hearing results from multiple studies over the next few years and there's every reason to hope now, with this news, that many of them will be positive," said Dr. Robert Vonderheide, director of Penn Medicine's Abramson Cancer Center and president-elect of the American Association for Cancer Research.
Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview. This is the first positive late-stage trial result for an mRNA cancer vaccine, which trains a patient's immune system to fight tumors by targeting specific mutations in those cells, and the first such study to show that adding a treatment to Keytruda worked better than that therapy alone... Interim results of the ongoing study, released on Wednesday, found the treatment, Intismeran, met both its primary target of reducing cancer recurrence and its secondary goal of preventing tumors from spreading to other parts of the body, compared with Keytruda alone. When the vaccine is injected into a patient, the patient's cells produce copies of mutations for the immune system to recognize and destroy... Merck said the companies are already in talks with regulators about the treatment.
"Merck, Moderna and other companies are testing similar approaches against lung, breast and pancreatic cancers," the article points out. It adds that Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, "said the Moderna results could signal a new era for treating solid-tumor cancers."
More from CNN:
The trial result is "a monumental leap forward," validating mRNA technology as a cancer treatment, said Dr. Julie Gralow, chief medical officer of the American Society of Clinical Oncology...
Roche and BioNTech, whose mRNA technology was used in the Pfizer COVID vaccines, are testing a similar treatment called autogene cevumeran in mid-stage studies in colon and pancreatic cancer patients who have undergone surgery. Results of the colon cancer trial are expected in 2027, with pancreatic trial results to follow in 2031. "We should be hearing results from multiple studies over the next few years and there's every reason to hope now, with this news, that many of them will be positive," said Dr. Robert Vonderheide, director of Penn Medicine's Abramson Cancer Center and president-elect of the American Association for Cancer Research.
Read more of this story at Slashdot.
47% of recent graduates say AI has already impacted hiring in their field, according to an April survey from ZipRecruiter.
"But is AI really the problem, or is it more complicated?" asks NPR. "Here's what economists have to say."
According to the Federal Reserve Bank of New York, the unemployment rate for recent graduates — which it defines as 22-to-27-year-olds with a new bachelor's degree or higher — was 5.7% as of June, more than the rate for all workers, which stands at 4.1%... Stanford University economist Erik Brynjolfsson says AI is impacting the labor market for entry-level roles. "AI is not the whole story, but it's part of the story and the evidence is building," he says. Using payroll data, Brynjolfsson and his co-authors found that since late 2022 — when large language models like ChatGPT started popping up — early-career workers ages 22 to 25 in AI-exposed roles, like software developers and marketing managers, have experienced a 16% relative employment decline. In comparison, employment rates for older workers in AI-exposed fields and for all workers in jobs that aren't easily automated — like home health aides, physical therapists and construction workers — remained stable or have grown over that same time period... [Though he also says often when companies pull back on hiring, they cut junior roles first.]
Harvard University economist David Deming isn't convinced that AI is to blame for the challenging early-career job market. "If you look very carefully at the timing, it looks like the decline in junior hiring actually started a bit like six months before ChatGPT was released. And so what that tells me is it's something else," Deming says. "I think it's more like remote work." A recent analysis from the New York Fed found that companies are less likely to hire recent college grads into roles that can be done remotely. As remote jobs increased following the COVID-19 pandemic, so did unemployment among younger college grads, the New York Fed found. The analysis also found that AI didn't explain the rise in unemployment among younger workers and that remote work was more of a driving force... Employers hiring for remote jobs may be less likely to choose an entry-level candidate because it's harder to train them from afar... [And with remote positions, there's many more senior candidates to choose from.]
And here's another thing to consider: University of Chicago economist Anders Humlum says if AI were replacing entry-level jobs, you'd expect to see companies that rely heavily on AI to hire fewer workers. But that's not what the data shows. Humlum points to a study done by the financial accounting firm Ramp and the workforce research company Revelio Labs. The study examined AI spending and employee head count across more than 21,000 U.S. firms, from early 2021 to early 2026. It found that at companies making the largest AI investments, entry-level head count grew by 12% over the two years following AI adoption.
"But is AI really the problem, or is it more complicated?" asks NPR. "Here's what economists have to say."
According to the Federal Reserve Bank of New York, the unemployment rate for recent graduates — which it defines as 22-to-27-year-olds with a new bachelor's degree or higher — was 5.7% as of June, more than the rate for all workers, which stands at 4.1%... Stanford University economist Erik Brynjolfsson says AI is impacting the labor market for entry-level roles. "AI is not the whole story, but it's part of the story and the evidence is building," he says. Using payroll data, Brynjolfsson and his co-authors found that since late 2022 — when large language models like ChatGPT started popping up — early-career workers ages 22 to 25 in AI-exposed roles, like software developers and marketing managers, have experienced a 16% relative employment decline. In comparison, employment rates for older workers in AI-exposed fields and for all workers in jobs that aren't easily automated — like home health aides, physical therapists and construction workers — remained stable or have grown over that same time period... [Though he also says often when companies pull back on hiring, they cut junior roles first.]
Harvard University economist David Deming isn't convinced that AI is to blame for the challenging early-career job market. "If you look very carefully at the timing, it looks like the decline in junior hiring actually started a bit like six months before ChatGPT was released. And so what that tells me is it's something else," Deming says. "I think it's more like remote work." A recent analysis from the New York Fed found that companies are less likely to hire recent college grads into roles that can be done remotely. As remote jobs increased following the COVID-19 pandemic, so did unemployment among younger college grads, the New York Fed found. The analysis also found that AI didn't explain the rise in unemployment among younger workers and that remote work was more of a driving force... Employers hiring for remote jobs may be less likely to choose an entry-level candidate because it's harder to train them from afar... [And with remote positions, there's many more senior candidates to choose from.]
And here's another thing to consider: University of Chicago economist Anders Humlum says if AI were replacing entry-level jobs, you'd expect to see companies that rely heavily on AI to hire fewer workers. But that's not what the data shows. Humlum points to a study done by the financial accounting firm Ramp and the workforce research company Revelio Labs. The study examined AI spending and employee head count across more than 21,000 U.S. firms, from early 2021 to early 2026. It found that at companies making the largest AI investments, entry-level head count grew by 12% over the two years following AI adoption.
Read more of this story at Slashdot.
